Risk of hepatocellular carcinoma among patients with hepatitis C virus cirrhosis treated with direct-acting antiviral therapy: An Australian experience

被引：0
|
作者：
Snell, J. [1 ,2 ]
Hong, T. [1 ]
Glasgow, S. [1 ]
Papaluca, T. [1 ]
New, K. [1 ]
Mcclure, T. [1 ]
Bell, S. [1 ]
Demeduik, B. [1 ]
Jeremiah, C. [1 ]
Tran, S. [1 ,2 ]
Phan, D. [1 ,2 ]
Jarman, M. [1 ,2 ]
Iser, D. [1 ]
Lust, M. [1 ]
Shaw, G. [1 ]
Desmond, P. [1 ]
Croagh, C. [1 ]
Visvanathan, K. [1 ]
Howell, J. [1 ]
Ryan, M. [1 ,2 ]
Thompson, A. J. [1 ,2 ]
机构：
[1] St Vincents Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2017年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [31] Survival benefits of direct-acting antiviral therapy in patients with decompensated hepatitis C cirrhosis
    Kim, W. R.
    Osinusi, A.
    Mannalithara, A.
    Schall, R. A.
    Brainard, D.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S84 - S84
  • [32] Risk of hepatocellular carcinoma and efficacy of direct-acting antivirals in patients with concurrent hepatitis C virus
    Harrod, Elizabeth
    Agarwal, Ritu
    Tabrizian, Parissa
    Rayapudi, Madhavi
    Ala, Aftab
    Fiel, Isabel
    Schwartz, Myron
    Dieterich, Douglas
    Friedman, Scott
    Saberi, Behnam
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E733 - E734
  • [33] Tumor progression and recurrence after direct-acting antiviral therapy for hepatitis C in patients with previously treated or active hepatocellular carcinoma
    Wong, M. Y. W.
    Mccaughan, G. W.
    Mason, S.
    Moore, B.
    Koorey, D. J.
    Bowen, D. G.
    Strasser, S. I.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 77 - 78
  • [34] Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy
    Majumdar, Avik
    Kitson, Matthew T.
    Roberts, Stuart K.
    DRUGS, 2015, 75 (08) : 823 - 834
  • [35] Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis
    Pearlman, Brian L.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (05) : 1551 - 1561
  • [36] Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
    Sung, Pil Soo
    Shin, Eui-Cheol
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (02) : 1 - 13
  • [37] Did Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Really Improve the Survival of Patients with Hepatocellular Carcinoma? Reply
    Singal, Amit G.
    Parikh, Neehar D.
    Murphy, Caitlin C.
    GASTROENTEROLOGY, 2020, 158 (06) : 1844 - 1844
  • [38] Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
    Lim, Nicholas
    Singh, Dupinder
    Jackson, Scott
    Lake, John R.
    GASTROINTESTINAL TUMORS, 2020, 7 (04) : 134 - 143
  • [39] Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents
    Hamoir, C.
    Horsmans, Y.
    Starkel, P.
    Dahlqvist, G.
    Dastis, S. Negrin
    Lanthier, N.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2021, 84 (01) : 25 - 32
  • [40] Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
    Kishta, Sara
    Tabll, Ashraf
    Kolaric, Tea Omanovic
    Smolic, Robert
    Smolic, Martina
    BIOMEDICINES, 2020, 8 (06) : 1 - 15
12345